there is no way Rebecca has been appointed as COO (soon to be CEO), and the company then initiating the world leading CDH17 trial, without a clear pathway forward in regards to capital.
we are THE leader in cell therapy for oncology in Australia. Analysts estimate CAGR of 30% per annum in this space. Interim
data in multiple CHM trials expected soon and perhaps early signals of efficacy from CDH17.
there is no way Rebecca has been appointed as COO (soon to be...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243067 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |